

**Supplemental Table 3. Comparison of clinical characteristics between patients with positive and negative CSF LGI1 antibodies<sup>#</sup>**

	<b>CSF LGI1 antibody positive (N=42 )</b>	<b>CSF LGI1 antibody negative (N=23 )</b>	<b>P value</b>
<b>Male/Female</b>	24/18	14/11	0.961
<b>Age at onset, y, mean±SD</b>	61.2±12.5	53.6±15.0	<b>0.034*</b>
<b>Symptom at diagnosis, n (%)</b>			
<b>Seizure</b>	37 (88.1%)	21 (91.3%)	1.0
<b>Cognitive deficit</b>	33 (78.6%)	12 (52.2%)	<b>0.027*</b>
<b>Psychosis</b>	14 (34.1%)	5 (21.7%)	0.297
<b>Consciousness disorder</b>	7 (16.7%)	2 (8.7%)	0.474
<b>Speech disorder</b>	1 (2.4%)	3 (13.0%)	0.118
<b>Personality change</b>	6 (19.4%)	7 (30.4%)	0.171
<b>Sleep disorder</b>	2 (4.8%)	2 (8.7%)	0.61
<b>Autonomic dysfunction</b>	4 (9.5%)	2 (8.7%)	1.0
<b>Limb weakness</b>	3 (7.1%)	3 (13.0%)	0.657
<b>Hyponatremia, n (%)</b>	21 (50.0%)	7 (30.4%)	0.128
<b>CSF findings, n (%)</b>			
<b>Cell count &gt; 5 cells/uL</b>	4 (10.0%)	5 (22.7%)	0.259
<b>Protein &gt; 0.45 g/L</b>	13 (33.3%)	4 (18.2%)	0.205
<b>Positive OB</b>	7 (18.9%)	0 (0.0%)	0.082
<b>EEG, n (%)</b>			
<b>Normal</b>	7 (16.7%)	5 (21.7%)	
<b>Epileptic discharge</b>	9 (21.4%)	10 (43.5%)	
<b>Slow wave</b>	6 (14.3%)	1 (4.3%)	0.345
<b>MRI, n (%)</b>			
<b>Normal</b>	21 (50.0%)	13 (56.6%)	
<b>Unilateral hippocampal lesion</b>	12 (28.6%)	3 (13.0%)	
<b>Bilateral hippocampal lesions</b>	9 (21.4%)	7 (30.4%)	0.457
<b>Tumor, n (%)</b>	3 (7.1%)	3 (13.0%)	0.332
<b>Initial treatment, n (%)</b>			
<b>Corticosteroid</b>	33 (78.6%)	18 (81.8%)	1.0
<b>IVIG</b>	20 (47.6%)	10 (43.5%)	0.683
<b>MMF</b>	4 (9.5%)	2 (8.7%)	1.0
<b>Antiepileptic drugs</b>	35 (92.1%)	21 (95.5%)	1.0
<b>Residual symptoms, n (%)</b>			
<b>Cognitive impairment</b>	18 (42.9%)	10 (43.5%)	0.58
<b>Epilepsy</b>	9 (21.4%)	3 (13.0%)	0.32
<b>Personality change</b>	4 (9.5%)	7 (30.4%)	0.168
<b>BI upon admission, mean±SD</b>	76.9±18.4	87.0±17.4	<b>0.036*</b>
<b>BI at discharge, mean±SD</b>	78.8±23.6	90.0±13.1	<b>0.016*</b>
<b>Relapse, n (%)</b>	8 (23.5%)	2 (9.1%)	0.285

<b>mRS upon admission, median (IQR)</b>	2 (1~3)	1 (1~1)	<b>0.003<sup>**</sup></b>
<b>mRS at 12 months, median (IQR)</b>	1 (0~2)	0 (0~1)	<b>0.023<sup>*</sup></b>

Abbreviations: SD, standard deviation; CSF, cerebrospinal fluid; OB, oligoclonal band; EEG, electroencephalography; MRI, magnetic resonance imaging; IVIG: intravenous immunoglobins; MMF, mycophenolate mofetil; BI, Barthel Index; mRS, modified Ranking scale; IQR, interquartile range. Bold values indicate statistical significance. \*P<0.05; \*\*P<0.01. # Two patients were excluded for analysis due to incomplete data.